Breaking News Instant updates and real-time market news.

M

Macy's

, GOOS

Canada Goose

09:18
08/10/17
08/10
09:18
08/10/17
09:18

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Macy's (M), up 1.5%... Canada Goose (GOOS), up 7.4%... Brinker (EAT), up 5.1%... Jack in the Box (JACK), up 1.7%... Live Nation (LYV), up 8.5%. DOWN AFTER EARNINGS: Blue Apron (APRN), down 14%... Kohl's (KSS), down 4.4%... CB&I (CBI), down 21.1%... Masonite (DOOR), down 15.8%. ALSO LOWER: TG Therapeutics (TGTX), down 1.4% after the independent Data Safety Monitoring Board recommended the company cease enrollment into the single agent TGR-1202 arm, while continuing enrollment into the TG-1101 + TGR-1202 arm.

M

Macy's

GOOS

Canada Goose

EAT

Brinker

JACK

Jack in the Box

$94.68

-0.16 (-0.17%)

LYV

Live Nation

APRN

Blue Apron

KSS

Kohl's

CBI

CB&I

DOOR

Masonite

TGTX

TG Therapeutics

$10.15

0.15 (1.50%)

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 14

    Aug

  • 26

    Sep

  • 09

    Nov

M Macy's

06/21/17
GDHS
06/21/17
NO CHANGE
GDHS
Nike-Amazon pact yet another department store headwind, says Gordon Haskett
Gordon Haskett analyst noted the reports of Nike (NKE) nearing a deal to sell directly on Amazon (AMZN), which he said wouldn't impact trends overnight but would represent another headwind for department stores, particularly J.C. Penney (JCP) and Kohl's (KSS), where the brand has a larger penetration than at Macy's (M) and Nordstrom (JWN). He keeps an Accumulate rating on Nordstrom, a Hold rating on Macy's and Reduce rating on both J.C. Penney and Kohl's.
06/07/17
GSCO
06/07/17
NO CHANGE
Target $25
GSCO
Neutral
Macy's price target lowered to $25 from $28 at Goldman Sachs
Goldman analyst Lindsay Drucker Mann lowerd Macy's price target to $25 from $28 to reflect weaker margin trends and operating earnings following the company's Investor Day. The analyst is encouraged by the detail around strategic initiatives and has confidence in -3-4% FY17 comp guidance range. Shares are Neutral rated.
05/12/17
COWN
05/12/17
NO CHANGE
Target $29
COWN
Market Perform
Macy's financial modeling worrisome, says Cowen
Cowen analyst Oliver Chen said the rapid transformation of consumers' shopping preferences presents ongoing challenges to Macy's and other retailers. He said the company needs to reinvent promotional techniques that currently are yielding poor store traffic and higher markdowns. Chen said from a financial modeling perspective he is worried, leading him to maintain his Market Perform rating on Macy's shares and cut his price target to $29 from $44.
05/12/17
SBSH
05/12/17
NO CHANGE
Target $23
SBSH
Neutral
Macy's price target lowered to $23 from $30 at Citi
Citi analyst Paul Lejuez lowered his price target for Macy's to $23 saying the company's results yesterday "stood out as extremely weak" amid disappointing quarters across the sector. The analyst keeps a Neutral rating on the shares.
GOOS Canada Goose

04/11/17
04/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. HSN, Inc. (HSNI) initiated with a Hold at Aegis. 2. BroadSoft (BSFT) initiated with a Neutral at Baird. 3. Canada Goose (GOOS) initiated with an Equal Weight at Morgan Stanley. 4. MuleSoft (MULE) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray, a Buy at Jefferies, an Equal Weight at Barclays, and a Neutral at JPMorgan, BofA/Merrill, and Goldman. 5. ProPetro Holding (PUMP) was initiated with an Outperform at Evercore ISI and Credit Suisse, an Overweight at Piper Jaffray, JPMorgan, and Barclays, a Strong Buy at Raymond James, and a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/17
BOFA
06/28/17
UPGRADE
BOFA
Buy
Canada Goose upgraded to Buy from Neutral at BofA/Merrill
04/11/17
MSCO
04/11/17
INITIATION
MSCO
Equal Weight
Canada Goose initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Jay Sole initiated Canada Goose with an Equal Weight and a C$24 price target saying shares are fully valued.
04/10/17
04/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Incyte (INCY) initiated with a Buy at Gabelli. 2. Canada Goose (GOOS) initiated with an Overweight at Barclays, while being initiated with an Outperform at BMO Capital, Wells Fargo, Credit Suisse, RBC Capital, and CIBC, a Buy at Goldman and Canaccord, as well as, a Neutral at BofA/Merrill, Nomura, and Baird. 3. Tesaro (TSRO) initiated with a Neutral at Janney Capital. 4. John Bean Technologies (JBT) initiated with an Outperform at BMO Capital. 5. Celsion (CLSN) assumed with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EAT Brinker

06/22/17
BMOC
06/22/17
UPGRADE
BMOC
Outperform
Brinker upgraded on industry outlook at BMO Capital
As noted earlier, BMO capital upgraded Brinker to Outperform from Market Perform. Analyst AndrewStrelzik upgraded the shares based on his belief that sectorwide restaurant comps will accelerate over the next several monhs due to weakening commodity prices. Target $40.
06/22/17
06/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Oracle (ORCL) upgraded to Outperform from Neutral at Wedbush with analyst Steve Koenig saying that the company's guidance for "roughly" double digit percentage fiscal 2018 earnings per share growth "looks achievable," while checks indicate that its PaaS and IaaS sales pipeline is strong. 2. Southwest (LUV) upgraded to Buy from Hold at Argus with analyst David Coleman saying shares have further upside. 3. Abercrombie & Fitch (ANF) upgraded to Hold from Sell at Wunderlich with analyst Eric Beder saying risk/rewards is balanced and remains cautious on the company's turnaround efforts. 4. CarMax (KMX) upgraded to Outperform from Sector Perform at RBC Capital with analyst Scot Ciccarelli saying that the company's comparable sales continue to beat expectations, and he thinks the company's sales should continue to be boosted by its improved use of Search Engine Optimization and declining used car valuations. 5. Brinker (EAT) upgraded to Market Perform from Underperform at BMO Capital with analyst Andrew Strelzik citing his belief that sector-wide restaurant comps will accelerate over the next several months due to weakening commodity prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/17
BMOC
06/22/17
UPGRADE
BMOC
Market Perform
Brinker upgraded to Market Perform from Underperform at BMO Capital
06/15/17
06/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Hold from Buy at Canaccord with analyst Michael Graham citing valuation. Graham maintained his $1,000 price target on Alphabet shares. 2. Mattel (MAT) downgraded to Neutral from Buy at DA Davidson with analyst Linda Bolton saying near-term business fundamentals have deteriorated after the company cut its dividend by 61%. 3. Brinker (EAT) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe saying he expects higher spending and weak industry trends to offset any possible sales improvement. 4. Terex (TEX) downgraded to Neutral from Buy at Goldman Sachs with analyst Jerry Revinch citing valuation. 5. Splunk (SPLK) downgraded to Neutral from Outperform at Wedbush analyst Steve Koenig citing the emergence of "meaningful competition," the "complexity" of its transition to the cloud, and "somewhat messy fundamentals." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
JACK Jack in the Box
$94.68

-0.16 (-0.17%)

06/02/17
WELS
06/02/17
UPGRADE
Target $125
WELS
Outperform
Jack in the Box upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jeff Farmer upgraded Jack in the Box to Outperform saying the potential sale of the Qdoba concept is not being fully reflected in the shares. Jack's valuation multiple would positively inflect with the improved EBITDA margin and free cash flow conversion profile that would come with a Qdoba sale, the analyst contends. He raised his price target for the shares to $125 from $114.
06/02/17
OPCO
06/02/17
NO CHANGE
Target $125
OPCO
Outperform
Jack in the Box risk/reward 'intriguing' in Qdoba sale, says Oppenheimer
Oppenheimer analyst Brian Bittner says his analysis identifies an "intriguing" risk/reward in Jack in the Box shares if Qdoba is sold. As a standalone, Jack in the Box would be "free to further improve cost structure, leverage and cap-ex versus estimates," the analyst tells investors in a research note. He reiterates an Outperform rating on the shares with a $125 price target. Wells Fargo this morning upgraded Jack in the Box on the potential Qdoba sale.
06/02/17
06/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wayfair (W) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the company's sales growth has been reaccelerating lately and its "inventory-light" business model is both powerful and underappreciated. 2. Estee Lauder (EL) and Ulta Beauty (ULTA) were upgraded to Buy from Hold at Jefferies. 3. Deere (DE) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying she likes the strategic fit of the Wirtgen Group acquisition and believes it will open up new markets for growth. 4. Jack in the Box (JACK) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jeff Farmer saying the potential sale of the Qdoba concept is not being fully reflected in the shares. 5. Fastenal (FAST) upgraded to Buy from Neutral at Longbow with analyst Chris Dankert saying distribution checks are at the highest level to date trending at 5.3% growth, an acceleration from 4.3% growth reported during March checks. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/17
OPCO
08/07/17
NO CHANGE
Target $125
OPCO
Outperform
Jack in the Box upside overlooked if Qdoba is sold, says Oppenheimer
Oppenheimer analyst Brian Bittner says near-term sales fears have buy-side overlooking special-sit dynamics in Jack in the Box's shares. While the analyst is not sure of the date Qdoba sale occurs, he views it as the easiest to execute path to create significant shareholder value. Bittner does not anticipate a spin or a refranchising of Qdoba. He reiterates an Outperform rating and $125 price target on the shares.
LYV Live Nation

06/19/17
06/19/17
DOWNGRADE

Neutral
Live Nation downgraded to Neutral on valuation at Northcoast
As previously reported, Northcoast downgraded Live Nation to Neutral from Buy. Analyst John Healy said fundamentals remain intact but changed his rating due to recent share outperformance.
06/27/17
JEFF
06/27/17
NO CHANGE
Target $40
JEFF
Buy
Live Nation price target raised to $40 from $36 at Jefferies
Jefferies analyst John Janedis raised his price target for Live Nation to $40 on expectations for a strong summer concert season. The stock should continue outperforming as the market gives the company more credit for "strong secular tailwinds" across the portfolio, the analyst tells investors in a research note. He keeps a Buy rating on Live Nation.
07/21/17
WBLR
07/21/17
INITIATION
WBLR
Outperform
Live Nation initiated with an Outperform at William Blair
William Blair analyst Ryan Sundby started Live Nation with an Outperform rating.
08/10/17
SPHN
08/10/17
NO CHANGE
Target $44
SPHN
Overweight
Live Nation price target raised to $44 from $36 at Stephens
Stephens analyst Kyle Evans raised his price target for Live Nation to $44 from $36 after the company posted "solid" Q2 results driven by "very impressive" growth in its Concerts business. The analyst reiterates an Overweight rating on the shares.
APRN Blue Apron

07/25/17
RHCO
07/25/17
INITIATION
Target $12
RHCO
Buy
Blue Apron initiated with a Buy at SunTrust
SunTrust analyst Youssef Squali initiated Blue Apron with a Buy and a $12 price target citing its leadership position in the emerging meal kit market and attractive valuation. The analyst is positive on Blue Apron's early levels of market penetration, sole focus on the meal-kit market and quality obsession, and strong management team.
07/25/17
SBSH
07/25/17
INITIATION
Target $10
SBSH
Buy
Blue Apron initiated with a Buy at Citi
Citi analyst Mark May started Blue Apron with a Buy rating and $10 price target. The online meal-kit market will likely produce one or two companies that scale over the next 10 years, May tells investors in a research note. He believes the shares could reach $10 over the next year if execution is "solid."
07/25/17
07/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Blue Apron (APRN) was initiated with a Buy at Citi and SunTrust. 2. Blue Buffalo Pet Products (BUFF) initiated with a Neutral at Baird 3. e.l.f. Beauty (ELF) initiated with a Buy at Citi. 4. Grainger (GWW) initiated with a Neutral at Northcoast. 5. Western Asset Mortgage (WMC) initiated with a Market Perform at JMP Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
STFL
08/04/17
NO CHANGE
STFL
Buy
Blue Apron not cutting staff levels, says Stifel
Stifel said Blue Apron is not cutting staff levels, but shifting its operations to the new Linden, NJ site later this year as part of a planned fulfillment-center migration process.
KSS Kohl's

08/02/17
08/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wal-Mart (WMT) initiated with an Outperform at Oppenheimer. 2. Kohl's (KSS) assumed with a Buy at Jefferies. 3. Jabil Circuit (JBL) initiated with an Overweight at JPMorgan. 4. Bank of the Ozarks (OZRK) initiated with an Overweight at Morgan Stanley. 5. Sequans (SQNS) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/17
OTRG
08/08/17
UPGRADE
OTRG
Mixed
Kohl's upgraded to Mixed from Negative at OTR Global
OTR Global raised its view on Kohl's to Mixed following checks that indicate Q2 sell-through at least met its plan with most vendors surveyed.
08/02/17
JEFF
08/02/17
INITIATION
Target $48
JEFF
Buy
Kohl's assumed with a Buy at Jefferies
Jefferies analyst Randal Konik assumed coverage of Kohl's (KSS) with a Buy rating and $48 price target. The analyst views the valuation as attractive amid negative sentiment and left recent store visits encouraged with trends in Active and the "positive reception" for Under Armour (UA, UAA) product.
06/27/17
OPCO
06/27/17
NO CHANGE
OPCO
Perform
Under Armour still expensive despite 25% decline, says Oppenheimer
Oppenheimer analyst Anna Andreeva says shares of Under Armour (UAA) remain expensive even with the 25% pullback year-to-date. The Q1 decline in North America sales is likely to continue in Q2 as the addition of Kohl's (KSS) isn't enough to offset store bankruptcies and a "choppy environment," Andreeva tells investors in a research note. She points out that Under Armour's annual sales guidance assumes North America recovers in the second half of 2017, aided by new distribution and expansion in existing franchises. Andreeva believes, however, that Nike's (NKE) focus on its own stores and adidas' (ADDYY) ongoing momentum may be too tough for Under Armour to overcome. The analyst keeps a Perform rating on the shares and her estimates for 2017 and 2018 remain below consensus.
CBI CB&I

08/10/17
SBSH
08/10/17
NO CHANGE
Target $18
SBSH
Neutral
Citi cuts CB&I target, doesn't see 'big liquidity risk'
Citi analyst Andrew Kaplowitz says the seemingly forced sale of CB&I's Technology business is more concerning than he expected. Cost overruns on two gas plants and two U.S. Gulf coast LNG projects that resulted in $548M charges in the quarter seemed to force the company's hand, Kaplowitz tells investors in a research note. The good news, the analyst writes, it that he doesn't see "big liquidity risk" for CB&I because Technology is a "significantly valuable asset that should have lots of interested buyers." The analyst is concerned, however, that the charges in Q2 are "more the start and not the end" of CB&I's challenges. Kaplowitz lowered his price target for the shares to $18 from $20 and keeps a Neutral rating on the name.
08/10/17
DADA
08/10/17
NO CHANGE
DADA
CB&I reported 'dismal' Q2 results, but weakness overdone, says DA Davidson
DA Davidson analyst Brent Thielman says that CB&I reported "dismal" Q2 results, and the analyst slashed his price target on the shares to $25 from $40. However, he still believes that the company's EPS will rise to $4 "over time," and he believes that the weakness in the stock is overdone. Thielman keeps a Buy rating on the shares.
08/10/17
BARD
08/10/17
NO CHANGE
Target $10
BARD
Neutral
CB&I target cut to $10, cash burn puts balance sheet back in focus, says Baird
Baird analyst Andrew Wittmann said CB&I took significant project charges that, along with further cash burn, prompted immediate actions to avoid balance sheet pressure, which is now back in focus. He sees the cash burn likely continuing with ample risk stemming from further project degradation. Wittmann maintained his Neutral rating and lowered his price target to $10 from $24 on CB&I shares.
08/10/17
DBAB
08/10/17
NO CHANGE
Target $21
DBAB
Buy
Deutsche Bank lays out path for CB&I shares getting back near $20
Deutsche Bank analyst Chad Dillard says that while CB&I's Q2 results "disappointed significantly," he sees a "clear path" to the shares trading towards the $20 range again should management execute and avoid further cos overruns. Selling the Technology business for 120% of the company's market value, deleveraging and reducing costs by $100M annually would unlock value, Dillard tells investors in a research note titled "2Q Results, A Tough (and Large) Pill to Swallow." The analyst lowered his price target for CB&I shares to $21 from $25 and maintains a Buy rating on the name. The stock in premarket trading is down 22%, or $3.58, to $12.75.
DOOR Masonite

05/10/17
RBCM
05/10/17
NO CHANGE
RBCM
Masonite should be bought on weakness, says RBC Capital
RBC Capital analyst Robert Wetenhall recommends buying Masonite on weakness after it reported weaker than expected results. The analyst says that the miss was probably caused by "manufacturing inefficiencies" and "inventory adjustments" by large retailers. He expects these issues to "be resolved," and he keeps a $92 price target and Outperform rating on the shares.
06/16/17
WEDB
06/16/17
INITIATION
WEDB
Outperform
Masonite coverage assumed with an Outperform at Wedbush
Wedbush analyst Jay McCanless assumed coverage of Masonite with an $85 price target and an Outperform rating. The analyst thinks that the company's strategy of focusing on the door market is correct, and he believes that it can meet the midpoints of its EBITDA and EPS guidance ranges.
08/10/17
SPHN
08/10/17
DOWNGRADE
SPHN
Equal Weight
Masonite downgraded to Equal Weight from Overweight at Stephens
05/10/17
BARD
05/10/17
NO CHANGE
Target $90
BARD
Outperform
Masonite growth story remains intact, says Baird
Baird analyst Timothy Wojs noted Masonite shares traded lower following its Q1 results as manufacturing inefficiencies in North America overshadowed relatively solid demand and good price/mix improvement. Wojs said despite the misstep, Masonite's growth story remains intact and he reiterated his Outperform rating and $90 price target on Masonite shares.
TGTX TG Therapeutics
$10.15

0.15 (1.50%)

03/13/17
RHCO
03/13/17
NO CHANGE
RHCO
TG Therapeutics data 'highly positive,' says SunTrust
SunTrust analyst Yatin Suneja says that the data on TG's CD20 antibody, TG-1101, was "highly positive." The analyst expects additional data on the drug due out in June to support its approval, and he thinks that the company has multiple potential positive turning points over the next 6-18 months. He raised his price target on the shares to $28 from $26 and keeps a Buy rating.
04/25/17
JEFF
04/25/17
INITIATION
Target $23
JEFF
Buy
TG Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started TG Therapeutics with a Buy rating and $23 price target. The company is undervalued based on the long-term promise of ublituximab, TGR-1202 and TG-1303 in B-cell cancers and multiple sclerosis, the analyst contends.
06/05/17
JEFF
06/05/17
NO CHANGE
Target $23
JEFF
Buy
TG Therapeutics data supportive of approval, says Jefferies
Jefferies analyst Matthew Andrews believes the data announced over the weekend by TG Therapeutics for TG-1101 plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia are supportive of approval. The hazard ratio of 0.56 is encouraging, Andrews tells investors in a research note. He views TG shares as undervalued and keeps a Buy rating on the name with a $23 price target.
06/16/17
RHCO
06/16/17
NO CHANGE
RHCO
TG Therapeutics data encouraging, says SunTrust
SunTrust analyst Yatin Suneja says that the follow-up Phase I/Ib data on TG's triplet combination in DLCL and FL is "encouraging." The analyst thinks that the data shows that the combination "is highly active and relatively well-tolerated." Suneja is encouraged by the results and expects an upcoming pre-BLA meeting with the FDA to be positive. The analyst keeps a $28 price target and a Buy rating on the shares.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.